Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• clinically defined lacunar syndrome 3 months before inclusion

• small deep infarct on diffusion MRI (Diffusion Weighted Imaging)

• no atherothrombotic, cardio-embolic, or other rarer cause.

Exclusion Criteria:

• patients with past coronary event

• contra-indication for assessment of vasomotor reactivity

• patients being on statin therapy at the time of brain infarction

• contra-indication for statin therapy

• patient still under statin therapy